A Two Part, Phase 1/2, Safety, PK and PD Study of TOL101, an Anti-TCR Monoclonal Antibody for Prophylaxis of Acute Organ Rejection in Patients Receiving Renal Transplantation.

Trial Profile

A Two Part, Phase 1/2, Safety, PK and PD Study of TOL101, an Anti-TCR Monoclonal Antibody for Prophylaxis of Acute Organ Rejection in Patients Receiving Renal Transplantation.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 31 Jul 2014

At a glance

  • Drugs TOL 101 (Primary) ; Antithymocyte globulin; Methylprednisolone; Mycophenolate mofetil; Prednisone; Tacrolimus
  • Indications Renal transplant rejection
  • Focus Adverse reactions; First in man
  • Sponsors Tolera Therapeutics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 10 Jun 2013 Planned end date changed from Jan 2012 to Jun 2013 as reported by ClinicalTrials.gov.
    • 10 Jun 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top